DrugPatentWatch Database Preview
DSUVIA Drug Profile
» See Plans and Pricing
Which patents cover Dsuvia, and what generic alternatives are available?
Dsuvia is a drug marketed by Acelrx Pharms and is included in one NDA. There are eighteen patents protecting this drug.
This drug has ninety-two patent family members in nineteen countries.
The generic ingredient in DSUVIA is sufentanil citrate. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the sufentanil citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dsuvia
A generic version of DSUVIA was approved as sufentanil citrate by WEST-WARD PHARMS INT on December 15th, 1995.
Summary for DSUVIA
| International Patents: | 92 |
| US Patents: | 18 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 19 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,226 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DSUVIA |
| What excipients (inactive ingredients) are in DSUVIA? | DSUVIA excipients list |
| DailyMed Link: | DSUVIA at DailyMed |
Recent Clinical Trials for DSUVIA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Montefiore Medical Center | Phase 4 |
| University of Minnesota | Phase 4 |
Pharmacology for DSUVIA
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
US Patents and Regulatory Information for DSUVIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Get Started for $10 | ||||
| Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Y | Get Started for $10 | |||
| Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Y | Get Started for $10 | |||
| Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Y | Get Started for $10 | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DSUVIA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3685829 | Get Started for $10 |
| South Korea | 20080084857 | Get Started for $10 |
| Germany | 602007007991 | Get Started for $10 |
| South Korea | 20090096747 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for DSUVIA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2114383 | 16C0010 | France | Get Started for $10 | PRODUCT NAME: SUFENTANIL; REGISTRATION NO/DATE: EU/1/15/1042 20150918 |
| 2114383 | 300797 | Netherlands | Get Started for $10 | PRODUCT NAME: SUFENTANIL, DESGEWENST IN DE VORM VAN SUFENTANILCITRAAT; REGISTRATION NO/DATE: EU/1/15/1042 20150922 |
| 2114383 | CR 2016 00007 | Denmark | Get Started for $10 | PRODUCT NAME: SUFENTANIL; REG. NO/DATE: EU/1/15/1042/001-006 20150922 |
| 2114383 | SPC/GB16/004 | United Kingdom | Get Started for $10 | PRODUCT NAME: SUFENTANIL; REGISTERED: UK EU/1/15/1042 20150922 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
